Innate Pharma S.A. (EPA:IPH)

Innate Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Assets

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	28.09	66.4	70.61	84.23	103.76
Short-Term Investments	6.22	14.37	21.85	17.26	16.08
Cash & Short-Term Investments	34.31	80.77	92.46	101.49	119.84
Cash Growth	-57.52%	-12.64%	-8.90%	-15.31%	-20.97%
Accounts Receivable	0.39	0.65	15.23	3.08	0.85
Other Receivables	7.22	0.99	31.26	27.94	12.63
Receivables	7.61	1.64	46.49	31.02	13.47
Prepaid Expenses	2.39	2.82	5.69	4.67	2.58
Other Current Assets	2.4	0.51	3.37	2.65	2.36
Total Current Assets	46.71	85.74	148.01	139.83	138.26
Property, Plant & Equipment	4.36	5.13	6.32	8.54	10.17
Long-Term Investments	10.46	10.28	9.8	35.12	39.88
Other Intangible Assets	-	-	0.42	1.56	44.19
Long-Term Deferred Tax Assets	-	-	-	-	5.03
Other Long-Term Assets	1.2	9.9	10.64	14.25	29.97
Total Assets	62.72	111.06	175.19	199.3	267.5

Liabilities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	7.48	7.92	8.56	13.66	14.73
Current Portion of Long-Term Debt	8.52	8.44	8.45	1.28	29.94
Current Portion of Leases	0.29	0.27	0.49	0.82	0.8
Current Income Taxes Payable	6.55	6.96	7.02	5.98	7.46
Current Unearned Revenue	9.33	8.06	13.51	16.78	19.92
Other Current Liabilities	4.5	1.33	1.61	2.82	7.03
Total Current Liabilities	36.65	32.98	39.64	41.34	79.89
Long-Term Debt	13.67	22.18	30.61	38.93	11.49
Long-Term Leases	0.1	0.1	0.35	1.22	2.01
Long-Term Unearned Revenue	31.75	43.95	49.65	60.91	58.41
Pension & Post-Retirement Benefits	1.92	2.73	2.44	2.55	2.98
Long-Term Deferred Tax Liabilities	-	-	-	-	5.03
Other Long-Term Liabilities	0.33	0.27	0.6	0.2	0.25
Total Liabilities	84.42	102.23	123.29	145.14	160.06

Shareholders' Equity

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	4.69	4.19	4.04	4.01	3.98
Additional Paid-In Capital	408.03	390.98	384.26	379.64	375.22
Retained Earnings	-435.54	-386.36	-336.89	-330.32	-272.21
Comprehensive Income & Other	1.12	0.03	0.5	0.82	0.46
Shareholders' Equity	-21.7	8.83	51.9	54.15	107.44
Total Liabilities & Equity	62.72	111.06	175.19	199.3	267.5

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	22.57	31	39.89	42.25	44.25
Net Cash (Debt)	11.74	49.78	52.56	59.23	75.59
Net Cash Growth	-76.42%	-5.30%	-11.26%	-21.63%	-42.98%
Net Cash Per Share	0.13	0.61	0.65	0.74	0.95
Filing Date Shares Outstanding	93.79	92.16	80.86	80.19	79.54
Total Common Shares Outstanding	93.7	83.83	80.86	80.19	79.54
Working Capital	10.06	52.76	108.38	98.49	58.37
Book Value Per Share	-0.23	0.11	0.64	0.68	1.35
Tangible Book Value	-21.7	8.83	51.49	52.6	63.25
Tangible Book Value Per Share	-0.23	0.11	0.64	0.66	0.80

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 2, 2026

Data Sources Report a data error